Overview
1. Anatomic/functional oncologic Imaging: SPECT/CT, PET/CT, novel PET radiotracers
2. Radiotheranostics, Radionuclide therapy of cancer, Radiation Therapy Planning
3. Imaging biomarkers for guiding treatment strategies
4. Multicenter clinical trial development (NCI National Clinical Trials Network)
2. Radiotheranostics, Radionuclide therapy of cancer, Radiation Therapy Planning
3. Imaging biomarkers for guiding treatment strategies
4. Multicenter clinical trial development (NCI National Clinical Trials Network)
Current Appointments & Affiliations
Professor of Radiology
·
2019 - Present
Radiology, Nuclear Medicine,
Radiology
Professor in Medicine
·
2020 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study
Conference JOURNAL OF CLINICAL ONCOLOGY · June 1, 2023 Link to item CitePhase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191
Conference JOURNAL OF CLINICAL ONCOLOGY · June 1, 2023 Link to item CiteThe GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
Journal Article J Geriatr Oncol · April 2023 INTRODUCTION: Pancreatic cancer is the fourth leading cause of cancer-related death in the US with an increasing incidence in older adults (OA) over age 70. There are currently no treatment guidelines for OA with metastatic pancreatic cancer (mPCA) and sel ... Full text Link to item CiteRecent Grants
Positron Emission Tomography using 64Cu-SAR-bisPSMA in participants with high-risk prostate cancer prior to radical prostatectomy: A prospective, single-arm, multi-center, blinded-review, Phase 3 diagnostic performance study
Clinical TrialPrincipal Investigator · Awarded by Clarity Pharmaceuticals Pty Ltd (Clarity Pharmaceuticals) · 2024 - 2027ECOG-ACRIN Operations Center - Clinical Trials
ResearchPrincipal Investigator · Awarded by ECOG-ACRIN Medical Research Foundation Inc. · 2019 - 2026Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy
Clinical TrialPrincipal Investigator · Awarded by Zionexa S.A.S. · 2023 - 2025View All Grants
Education
Dartmouth College ·
1990
M.D.
Dartmouth College ·
1990
Ph.D.